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PENILAIAN EKONOMIK DAN NILAI KESANGGUPAN UNTUK 
MEMBAYAR UNTUK VAKSIN DENGGI DI MALAYSIA 
 
ABSTRAK 
 Penyakit denggi menyumbang kepada beban kesihatan dan ekonomik yang 
tinggi di Malaysia. Kajian ini dibahagikan kepada dua fasa. Fasa-1 menilai impak 
dan kos keberkesanan vaksin denggi dengan menggunakan satu model matematik 
transmisi dinamik dari perspektif pembekal awam dan masyarakat. Model tersebut 
menggabungkan data epidemiologi yang khusus kepada Malaysia, data keberkesanan 
bersepadu dan keselamatan jangka panjang dari kajian klinikal fasa-III, dan analisa 
kepekaan untuk memperbaiki anggaran daripada kajian-kajian sebelumnya. Fasa-2 
menilai penerimaan dan nilai kesanggupan-untuk-membayar (WTP) untuk vaksin 
denggi di antara masyarakat umum di Pulau Pinang dengan menggunakan kaedah 
keratarentas dan penilaian kontingen. Kaedah pembahagian dua-tahap dengan teknik 
pembidaan telah digunakan untuk memperolehi jumlah WTP. Nilai purata WTP dan 
faktor-faktor yang mempengaruhi nilai WTP ditentukan dengan kaedah parametrik 
permodalan dua tahap (TPM). Hubungan antara penerimaan vaksin denggi dengan 
faktor-faktor yang mempengaruhinya dianalisa dengan modal regresi logistik 
univariat. Dalam kajian fasa-1, keenam-enam program vaksinasi denggi 
menghasilkan manfaat yang positif dalam aspek pengurangan kes-kes denggi, 
kematian, kelangsungan hidup terlaras hilang upaya (DALY), dan kos rawatan 
denggi. Kos keberkesanan vaksin denggi dianalisa dengan pengiraan nilai ambang 
untuk sangat kos-berkesan (ICER<1x GDP/kapita) dan kos-berkesan (ICER=1–3x 
GDP/kapita). Kajian mendapati bahawa program pemvaksinasi denggi adalah kos 
berkesan sehingga harga maksimum US$28.59-87.49 dan sangat kos berkesan 
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sehingga harga maksimum US$12.60-42.27 dari perspektif pembekal awam. Kos 
keberkesanan adalah peka terhadap faktor kurang lapor, tempoh perlindungan vaksin, 
dan tempoh masa model. Vaksinasi rutin untuk orang awam berumur 13 tahun 
dengan tangkapan di antara golongan orang awam berumur 14–30 tahun di kawasan 
titik sasaran merupakan program yang paling bernilai. Dalam kajian fasa-2, hasil 
kajian menunjukkan bahawa 88.4% responden menerima vaksin denggi untuk 
dewasa. Analisis regresi menunjukkan bahawa penerimaan vaksin dipengaruhi oleh 
pengetahuan denggi (OR 1.426), sikap terhadap vaksinasi (OR 1.909), dan  etnik 
Cina (OR 0.359). Nilai purata WTP adalah RM83.19 (US$18.80). Anggaran logit 
daripada TPM menunjukkan bahawa responden yang mempunyai anak, dengan 
peringkat pendidikan yang tinggi, dan pesara adalah lebih cenderung untuk 
membayar untuk vaksin denggi. Regresi kedua dalam model TPM menganggarkan 
nilai WTP yang lebih tinggi dalam kalangan pesara dan responden dengan skor 
amalan pencegahan denggi yang lebih tinggi. Vaksin denggi adalah pelaburan yang 
berpotensi tinggi jika pembeli boleh berunding untuk membelinya dengan harga 
yang kurang daripada nilai ambang kos-berkesan. Vaksin denggi didapati amat 
diterima oleh orang awam, di mana ia menunjukkan nilai yang tinggi untuk vaksin 











ECONOMIC EVALUATION AND WILLINGNESS TO PAY (WTP) 
ELICITATION OF DENGUE VACCINE IN MALAYSIA 
 
ABSTRACT 
 Dengue disease poses great health and economic burden in Malaysia. This 
study was divided into two phases. Phase-1 evaluated the impact and cost-
effectiveness of dengue vaccine employing a dynamic-transmission mathematical 
model from both public provider and societal perspective. The model integrated 
Malaysia-specific epidemiological data, pooled efficacy and long-term safety data 
from phase-III clinical studies, and sensitivity analyses to refine the estimates from 
previous studies. Phase-2 assessed the acceptance and willingness-to-pay (WTP) 
value of dengue vaccine among Penang general population utilizing a cross-sectional, 
contingent-valuation approach. A double-bounded dichotomous-choice approach was 
applied in eliciting the WTP amount via bidding game method. The mean WTP 
value and the factors affecting the WTP value were determined by a parametric two-
part model (TPM). The association between dengue vaccine acceptance and its 
determinants was analysed by a univariate logistic regression model. In phase-1 
study, all six vaccination programmes produced positive benefits expressed in the 
reduction in dengue cases, dengue-related-deaths, disability-adjusted-life-years 
(DALY), and treatment cost. The cost-effectiveness of dengue vaccination was 
evaluated by calculating the threshold values for highly cost-effective (ICER<1x 
GDP/capita) and cost-effective (ICER=1–3x GDP/capita). The study found that 
dengue vaccination is cost-effective up to a price of US$28.59-87.49 and highly cost-
effective up to a price of US$12.60-42.27 from provider perspective. The cost-
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effectiveness is sensitive to underreporting factor, vaccine protection duration, and 
model time horizon. Routine vaccination for 13-year-old with catch-up cohort 14–
30-year-old in targeted hotspot appeared to be the best-valued programme. In phase-
2 study, results showed that 88.4% of the respondents accepted the adult vaccine. 
The regression analysis showed that the vaccine’s acceptance was affected by dengue 
knowledge (OR 1.426), vaccination attitude (OR 1.909), and Chinese ethnicity (OR 
0.359). The mean WTP was RM83.19 (US$18.80). The logit estimation from TPM 
showed that respondents with children, with higher education level, and pensioners 
were more likely to pay for the vaccine. The second-stage regression of TPM 
estimated a significant higher WTP amount from pensioners and respondents with 
higher household dengue prevention practice score. Dengue vaccination is a 
potentially good investment if the purchaser could negotiate a price below the cost-
effective threshold price. Dengue vaccine is highly acceptable by the public, which 








Dengue disease is the most common arthropod-borne viral illness affecting human 
population found in major tropical and subtropical areas worldwide. Malaysia has been 
experiencing a surge of dengue cases in recent years; with 43,346 cases in 2013 that 
doubled to 111,285 cases in 2015 (World Health Organization, 2016b). However, 
existing studies have shown that dengue cases in Malaysia could be under-reported 
(Shepard et al., 2012, Undurraga et al., 2013). Several studies found that the annual 
economic burden of dengue in Malaysia ranges from US$78 million to US$311 million 
(Lee Han et al., 2010, Shepard et al., 2012, Shepard et al., 2013a, Shepard, 2013b). 
WHO Global strategy for dengue prevention and control has identified dengue vaccine 
implementation as one of the key elements in combating dengue disease (World Health 
Organization, 2012b). Nevertheless, the potential impact and cost-effectiveness of 
dengue vaccine have yet to be assessed in Malaysia. A country-specific economic 
evaluation of a new healthcare intervention is crucial to inform decision making and 
facilitate its implementation. In addition, the determination of the public’s willingness 
to pay for a hypothetical dengue vaccine explores its potential for selling in the private 
markets. This would help the public healthcare decision makers as well as vaccine 
manufacturers to devise strategies in the implementation of vaccination campaign. 
 
1.1 Dengue prevention and control strategy 
The WHO Global strategy for dengue prevention and control (2012–2020) (World 
Health Organization, 2012b) aimed to reduce 50% of  the dengue-related mortality and 
25% of the morbidity by 2020 . The strategy advocated 5 technical elements:  
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1) Diagnosis and case management: the implementation of a timely and 
appropriate clinical management, which involves early clinical and laboratory 
diagnosis, intravenous rehydration, staff training and hospital reorganization, aims to 
reduce dengue-related mortality to almost zero. 
2) Integrated surveillance and outbreak preparedness: the surveillance system 
for dengue should be a part of the national health information system. In addition, a 
harmonized effort across national dengue surveillance systems is needed for to obtain 
the critical data of the disease’s burden. A well-prepared outbreak handling should be 
based on well-developed contingency plans that are broadly disseminated and 
thoroughly understood and pre-tested before an epidemic. 
3) Sustainable vector control: effective vector control measures are critical to 
achieving and sustaining reduction of morbidity attributable to dengue. Since the 
preventive and vector control interventions aim to reduce dengue transmission, thereby 
decreasing the incidence of the infection and preventing outbreaks of the disease. This 
element also advised that countries should adopt the integrated vector management 
approach to vector control as promoted by WHO and define it as a rational decision-
making process to optimize the use of resources for vector control. The approach aims 
to improve efficacy, cost effectiveness, ecological soundness, and sustainability of 
vector control interventions. Dengue vector control is most amenable to the 
implementation of the principles of integrated vector management, which ensure 
judicious use of insecticides in combination with other prevention and control 
interventions.  
4) Future vaccine implementation: the current dengue prevention and control 
strategies should include vaccines as an essential element to anticipate and prepare for. 
This includes preparing for future decision-making on vaccine introduction and use, 
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considering the integration of vaccines with other tools for dengue prevention and 
control, and investments in surveillance systems and safety monitoring of vaccines.  
5) Basic operational and implementation research: this element emphasized the 
importance of research, and recommended that all party should promote and support 
the efforts. 
 
1.1.1 Vector control and surveillance 
As described above, the second and third elements of the WHO Global strategy for 
dengue prevention and control (2012–2020) advocate the integrated surveillance and 
sustainable vector control. However, currently, the only method to control the disease 
transmission in Malaysia is through active dengue surveillance and vector control 
interventions, as there are no specific treatment or licensed vaccine in Malaysia to 
protect against the disease. The Ministry of Health (MOH) Malaysia regards vector 
control as a gold standard for the prevention of dengue outbreaks although vector 
control has been shown to be only partially effective in reducing the disease burden 
(Horstick et al., 2010). Malaysia spent US$73.5 million or 0.03% of the country’s GDP 
on its National Dengue Vector Control Program on year 2010 (Packierisamy et al., 
2015). However, vector control effort is often constrained due to the lack of 
community support and involvement.  
 
1.1.1(a) National Dengue Strategic Plan (NDSP) 
In a continuous effort to combat dengue illness, MOH Malaysia has introduced and 
implemented NDSP in 2011 to enhance the dengue control strategies. The employed 
strategies include enhancing dengue surveillance, vector control, case and outbreak 
management, population mobilization and research in innovative dengue control tools 
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and strategies (Mudin, 2015). Moving forward, NDSP (2015-2020) adopted 7 new 
strategies to combat dengue including dengue surveillance, national cleanliness policy 
and integrated vector management, management of dengue cases, social mobilization 
and communication for dengue, dengue outbreak response, dengue research, and 
reduction of dengue burden in the Klang Valley (Ministry of Health Malaysia, 2015). 
In addition, new tool and strategy including residual sprays (a deltamethrin-based 
insecticide) in hotspot area and vaccination programme have been proposed in the 
updated NDSP. Deltamethrin is a synthetic compound that is currently used to control 
pests in agriculture, gardens, and pets. It has a broad-spectrum effect, which means 
that it would also be effective in killing most species of mosquitoes and other insects. 
 
1.1.2 Dengue vaccine 
Element 4 of the WHO Global strategy for dengue prevention and control (2012–2020) 
advocates the use of dengue vaccine as a tool for dengue prevention. Dengue vaccine 
appears to be a promising supplementary tool in controlling dengue disease as current 
dengue prevention strategies are limited to mosquito control. In most settings, such 
strategies have been proven to be partially effective or difficult to sustain due to the 
expansion of A.aegypti populations, mosquito and virus dispersal through extensive 
human travel networks, fragile vector control system, insufficient resources, lack of 
political will, and ineffective implementation of existing tools and strategies ( Horstick 
et al., 2010, Reiner et al., 2016). At individual level, dengue vaccine could be 
beneficial to reduce the probability of infection after bitten by an infected mosquito, 
thus reducing the probability of severe disease or the probability to transmit the virus 
to a mosquito to bite him/her. On the other hand, at population level, dengue vaccine 
could reduce the overall transmission, thus providing herd immunity even to 
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unvaccinated people. WHO Global strategy for dengue prevention and control has 
identified dengue vaccine implementation as one of the five technical elements in 
combating dengue disease (World Health Organization, 2012b).  
Ideally, a successful dengue vaccine should be minimally reactogenic and elicit 
strong, balanced and durable immune responses simultaneously to all 4 DENV 
serotypes upon one or two administrations. However, in reality, some or all these ideals 
could not be met due to immune enhancement and vaccine induced antibodies may 
predispose recipients to severe disease in the case of imbalanced responses against the 
four serotypes. As dengue is a human disease, the absence of satisfactory dengue 
animal disease model further complicates the study of the dengue pathogenesis and the 
immune response to the vaccine. Furthermore, the difficulties in the design and 
conduct of the dengue efficacy studies present challenges to the vaccine development 
(Wallace et al., 2013). 
 
1.1.2(a) Dengue vaccine development 
The first dengue vaccine, Sanofi Pasteur tetravalent chimeric yellow-fever dengue 
(CYD-TDV or Dengvaxia®) vaccine, was licensed in Mexico in December 2015 and 
subsequently registered in 4 countries including the Philippines, Brazil, El Salvador, 
and Costa Rica. Dengvaxia® uses the yellow fever 17D vaccine as its backbone as the 
live, attenuated yellow fever 17D vaccine was previously deemed to be the world’s 
safest and the model for the development of other live virus vaccines including polio, 
measles, mumps and varicella. As such, live vaccines against other flaviviruses, such 
as Japanese encephalitis virus, West Nile virus, and dengue viruses, based on the 
yellow fever 17D virus vaccine began to be developed (Monath et al., 2015). At least 
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eight other countries in Asia and Latin America including Singapore, Malaysia, 
Thailand and Indonesia are actively considering its licensure (Pang, 2016).  
Dengvaxia® is licensed in individuals age 9-45 years living in endemic areas 
administered on a 0/6/12-month schedule. The safety and efficacy of CYD-TDV has 
been evaluated in 2 parallel Phase 3 randomized clinical trials, i.e. CYD14 and CYD 
15. CYD 14 was conducted at sites in 5 countries in Asia (Indonesia, Malaysia, 
Philippines, Thailand and Vietnam) with 10,275 participants aged 2-14 years at first 
vaccination while CYD 15 was conducted at sites in 5 countries in Latin America 
(Brazil, Colombia, Honduras, Mexico and Puerto Rico) (Capeding et al., Villar et al., 
2015).  
The recent review states that the pooled vaccine efficacy against symptomatic 
virologically-confirmed dengue (VCD) of any serotype in the year starting 1 month 
after the third dose was 59.2% (95%CI 52.3 – 65.0) (Hadinegoro et al., 2015). Vaccine 
efficacy was found to be higher against DENV-3 (71.6%) and DENV-4 (76.9%) than 
against DENV-1 (54.7%) and DENV-2 (43.0%). Pooled vaccine efficacy for 
symptomatic dengue during the first 25 months were 60.3% (95% CI, 55.7 to 64.5) for 
all participants. Surprisingly, the efficacy for those 9 years of age or older were higher 
(65.6%) than for those younger than 9 years of age (44.6%). The results of long-term 
safety follow up showed an unexplained increased risk of hospitalization and severe 
dengue among participants younger than 9 years old in the third year after receipt of 
the first dose (RR = 7.45, 95% CI 1.15, 313.80), though this is dissipated in year 4 and 
5. The biologic mechanism behind this increased risk is currently not understood but 
may be related to naïve vaccine serostatus and/or age. 
Nevertheless, a lower risk of hospitalization was observed among children 
between the ages of 9 and 16 years compared to control group for up to 2 years after 
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completion of the three-dose vaccination schedule. There was no other safety signal 
has been identified. 
 
Dengue vaccine candidates in phase III and phase II clinical trials 
Several other dengue vaccine candidates are currently undergoing various phases of 
rapid development, including the 2 most advanced candidates (Takeda’s DENVax-
TDV and Butantan Institute’s TetraVax-DV-TV003) which are under evaluation in 
Phase 3 trials. The properties of these vaccine candidates are summarized in Table 1.1. 
TV003 and TV005 developed by the US National Institutes of Health (NIH) are based 
on wild-type strains with genetic mutations to attenuate the virus (Schwartz et al., 
2015). Both the vaccines have been licensed to several manufacturers, including 
Butantan, VaBiotech, and Merck. Phase 2 studies are currently ongoing in Brazil and 
Thailand, and a Phase 3 trial led by Butantan began in February 2016 (Whitehead, 
2016, Butantan Institute). 
TDV developed by Takeda is also a tetravalent live recombinant vaccine with 
a wildtype DEN2 strain attenuated in primary dog kidney cells and further attenuated 
by mutation in NS3 gene with whole virus DENV2 and recombinant DENV1/3/4 in 
DENV2 backbone (Schwartz et al., 2015). Various ongoing and completed Phase 1 
and Phase 2 trials have evaluated the variation of the 2 doses formulations and routes 
of administration (George et al., 2015, Osorio et al., Rupp et al., 2015). An ongoing 
Phase 3 trial has being carried out since April 2016 (Takeda). 
 
Dengue vaccine candidates in phase I clinical trials and pre-clinical development 
There are 4 candidates currently under development in Phase 1 trial (Table 1.1) 
including a tetravalent purified-inactivated vaccine by GSK (Martinez et al., 2015), a 
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tetravalent recombinant subunit vaccine based on the dengue wild-type pre-membrane 
and truncated envelope protein by Merck (Coller et al., 2011, Govindarajan et al., 
2015), a monovalent plasmid DNA vaccine by US Navy Medical Research Center 
(NMRC) (Beckett et al., 2011), and an inactivated vaccine/live attenuated vaccine 
heterologous prime boost by Walter Reed Army Institute of Research (WRAIR) (U.S. 
Army Medical Research and Materiel Command). 
There are currently 16 vaccines undergoing rapid pre-clinical development 
(Vannice et al., 2016) (Table 1.1) including 3 recombinant subunit vaccines, a 
tetravalent DNA vaccine, a virus-like particles (VLP) vaccine, 2 virus-vectored 
vaccines, 3 tetravalent purified-inactivated virus vaccines, 4 live-attenuated virus 
vaccines, a heterologous prime-boost and a simultaneously administered vaccine.
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Table 1.1: Dengue vaccines currently available or undergoing rapid clinical development 
Vaccine 
Candidate 






Yellow fever 17D vaccine backbone, pre-








(Vannice et al., 2016, Schwartz 









Wildtype strains with genetic mutations to 
attenuate the virus. DENV1, 3, and 4 are based on 
whole virus whereas DENV 2 is recombined in 
DENV4 backbone 
Phase III 
(Vannice et al., 2016, Butantan 







Wildtype DEN2 strain attenuated in primary dog 
kidney cells and further attenuated by mutation in 
NS3 gene with whole virus DENV2 and 
recombinant DENV1/3/4 in DENV2 backbone 
Phase III 
(Vannice et al., 2016, Takeda, 








Non-attenuated viruses of the 4 virus strains 
(DENV-1 to DENV-4), propagated in Vero cells, 
purified, and inactivated with formalin 
Phase I 
(Vannice et al., 2016, U.S. 
Army Medical Research and 
Materiel Command, Schwartz et 




Wildtype pre-membrane and truncated envelope 
protein via expression in the Drosophila S2 cell 
expression system 
Phase I 
(Vannice et al., 2016, Schwartz 
et al., 2015, Coller et al., 2011, 





Pre-membrane and envelope proteins of DENV1 
are expressed under control of the human 
cytomegalovirus promoter/enhancer of the plasmid 
vector VR1012 
Phase I 
(Vannice et al., 2016, Schwartz 








Heterologous prime-boost with live attenuated 
tetravalent, live attenuated vaccine and tetravalent 
alum-adjuvanted purified inactivated vaccine 
Phase I 
(Vannice et al., 2016, U.S. 








Developer Vaccine Type 
Mechanism of attenuation 
or inactivation 
Status References 
DIII-C IPK/CIGB Recombinant subunit 
EDIII-p64k fusion proteins 
and EDIII-capsid fusion 
proteins expressed in E. coli 
Pre-clinical 
(Vannice et al., 2016) 
- VaxInnate Recombinant subunit 
Bivalent 80E-STF2 fusion 
proteins expressed in 
baculovirus/insect cells 
Pre-clinical 
- NHRI Recombinant subunit 
Tetravalent consensus EDIII 
protein expressed in E. coli 
Pre-clinical 
- US CDC Tetravalent DNA 
prM/E expressed from 
plasmid vector DNA 
vaccine 
Pre-clinical 
- ICGEB VLP 
EDIII-HBsAg VLPs or 
ectoE-based VLPs 






Tetravalent EDIII and 
DENV-1 ectoM expressed 
from live-attenuated 
measles virus vector 
Pre-clinical 
- Global Vaccines Virus-vectored 
E85 expressed from single-
cycle VEE virus vector 
Pre-clinical 
- US NMRC Purified inactivated Psoralen-inactivated DENV Pre-clinical 
- FIOCRUZ Purified inactivated Purified inactivated DENV Pre-clinical 






Table 1.1-2 continued: Dengue vaccines currently available or undergoing rapid clinical development 
Vaccine 
Candidate 
Developer Vaccine Type 




Chiang Mai University, 
Mahidol University, 
NSTDA and BioNet-Asia 
Live attenuated 
DEN/DEN chimeric viruses, 
live, attenuated 
Pre-clinical 
(Vannice et al., 2016) 
- Arbovax Live attenuated 
DEN host range mutations, 
live, attenuated 
Pre-clinical 
- Beijing Institute Live attenuated 




Novartis Institute for 
Tropical Diseases/ 




DEN targeted mutation (2′-O-
methyltransferase mutant), live, 
attenuated 
Pre-clinical 
- NMRC/WRAIR Heterologous prime-boost 
Plasmid vector expressing 
prM/E (prime) and live 
attenuated DENV (boost) 
Pre-clinical 
- FIOCRUZ Simultaneous administration 
DENV prM/E expressed from 
live attenuated chimeric YF 





1.1.3 Health education and community campaign 
Primary prevention of dengue disease is a very important objective in combating the 
virus transmission. The strategy in primary prevention mainly revolves around health 
education and active participation from the community. Various studies have 
highlighted the importance of community health education and campaigns in vector 
reducing strategy. The health education and community-based dengue control 
approach were found to be at least as effective or cost-effective as chemicals larvicides 
(Espinoza-Gómez et al., 2002, Baly et al., 2009, Sanchez et al., 2009).  
The WHO, in its Handbook for Integrated Vector Management (IVM) (World 
Health Organization, 2012c), recommends the frequent communication with the 
general public to create awareness. This will drive behavioural change and empower 
people to become involved in the analysis and decision-making and adopt good dengue 
prevention practices. Among the tools advocated in the WHO-IVM handbook for 
reaching the public include the media, educational interventions, communication and 
farmer field schools to increase knowledge and skills. In the other hand, the WHO also 
developed the Communication for Behavioural Impact (COMBI) programme to 
promote communication, advocacy and social mobilisation in neighbourhoods, 
educational and workplace settings (World Health Organization and UNICEF, 2012). 
COMBI emphasises the role of knowledge, attitude and practice (KAP) surveys in 
recognizing key barriers to favourable behaviours regarding dengue. 
Nevertheless, existing literatures on KAP among Malaysian show mixed 
results and conclusions. Aung et al  found 54.6% of the rural Terengganu population 
had good dengue-related knowledge and 91.7% performed good practices against 
dengue infection (Aung et al. 2016). However, only 18.6% of them had good attitude 
against dengue infection. In contrast, Al-Zurfi et al found that majority of the students 
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from Shah Alam high school had good knowledge and attitude but only 26% of them 
performed good practice against dengue infection (Al-Zurfi et al., 2015). 
 
1.2 Epidemiology of dengue disease  
The World Health Organization (WHO) reported a 30-fold increase in annual dengue 
cases in the last 50 years with a mortality rate of 2.5% among severe dengue cases. 
Approximately 3.9 billion people globally are at risk, with 390 million infections 
occurring annually, and 68% of cases occurring in Asia (Bhatt et al., 2013). Malaysia 
has been experiencing a surge of dengue cases in recent years; with 43,346 cases in 
2013 that doubled to 111,285 cases in 2015 (World Health Organization, 2016b). 
Local epidemiology study found that states in west peninsular Malaysia are most 
affected by dengue, with dengue hotspot concentrated in Klang Valley, Kelantan, 
Penang, and Hulu Langat (Hii et al., 2016). Nevertheless, existing studies have shown 
that dengue cases in Malaysia could be under-reported (Shepard et al., 2012, 
Undurraga et al., 2013).  
Dengue is mainly caused by dengue viruses transmitted by female Aedes aegypti 
mosquitoes and to a lesser extent Aedes albopictus and Aedes polynesiensis (Halstead, 
2007). The dengue transmission dynamics are influenced by multiple complex risk 
factors including host immunity, vector capacity, circulating dengue virus serotypes, 
weather or climate, dengue control capacity, increasing urbanization and population 
movement (Ooi and Gubler, 2009, Hii et al., 2016). There are currently 4 known 
dengue virus serotypes which are antigenically distinct but immunologically closely 
related; namely DENV-1, DENV-2, DENV-3 and DENV-4 (World Health 
Organization, 2009). Early studies have shown that Malaysia is dengue hyper-
endemic, with all four serotypes circulating concurrently and with an abundance of 
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both Aedes aegypti and Aedes albopictus ( Chen et al., 2006, Chew et al., 2012). Over 
the past few decades, major dengue outbreaks occurred in a cyclical pattern of 
approximately 8 years, involving mainly DENV-1, DENV-2, and DENV-3 serotypes 
(Hii et al., 2016).  
Dengue exhibits a broad spectrum of clinical manifestation and its clinical 
evolution and outcome are often unpredictable. There are currently 3 known 
manifestation of dengue; namely dengue fever (DF), dengue haemorrhagic fever 
(DHF) and dengue shock syndrome (DSS) (World Health Organization, 2009). DF 
and DHF are identified as the major cause of mortality and morbidity in tropical and 
subtropical countries (Gubler, 1998). Fatality rate of DHF can be as high as more than 
20% without proper facility or treatment, however, if adequately treated, it could be 
reduced to less than 1% (World Health Organization, 2015). On the other hand, DSS 
accounts for more than 72% of common cause of death in dengue patients in Malaysia 
(2013-2014), followed by severe organ dysfunction (69%) and severe bleeding 
(29.7%) (Woon et al., 2016). Dengue case fatality rate (CFR) was found to be 
relatively constant at 0.2-0.3% although the number of death due to dengue disease 
increases from 45 to 134 from year 2000 to 2010. However, it was also found that 
there was an unusual spike of CFR in 2000 (0.63%) (Mohd-Zaki et al., 2014). 
  
1.3 Health and economic burden of dengue disease  
The social and economic impact concerning dengue disease is relatively high, thus, 
quantifying its health and economic burden is crucial for decision makers to prioritize 
policy setting and to form strategic control implementation based on informed 
decisions about the disease. 
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Suaya et al presented the first multicounty estimate of the direct and indirect 
cost of dengue cases in 8 countries across America and Asia including Malaysia. The 
total estimated average annual dengue cases were 574,000 for these 8 countries during 
2001–2005. The estimated total economic burden associated with dengue was US$238 
million, with Brazil and Thailand responsible for 94% and 60% of the aggregate cost 
in the American and Asian study countries, respectively. The estimated average annual 
dengue cases and deaths for Malaysia over the study period were 31,000 and 86, 
respectively. The estimated economic burden of dengue in Malaysia totalled up to 
US$38.2 million annually (Suaya et al., 2009). Nevertheless, subsequent studies found 
that the annual economic burden of dengue in Malaysia ranges from US$78 million to 
US$311 million with annual 143,891 dengue cases and 162 deaths (Lee Han et al., 





1.4 Problem statement 
The huge dengue disease economic and health burden in Malaysia poses a growing 
challenge to both the public health officials as well as the policymakers. Success in 
tackling this global threat is contingent on strengthening the evidence base on which 
control planning decisions and their impact are evaluated (Bhatt et al., 2013). 
The newly introduced dengue vaccine marks a new era in the humankind long 
battling with dengue disease. Dengue vaccine has been perceived as a promising 
solution for combating dengue, in view with the rising tide of dengue fever and its 
associated morbidities and mortalities. Furthermore, the vector control has not shown 
effective results in the prevention of dengue virus transmission, probably due to 
operational constraints as well as the inherent weakness in the programme delivery 
method (Shepard et al., 2004).  
Nevertheless, the potential impact and cost-effectiveness of dengue vaccine 
have yet to be assessed in Malaysia. At present, there is no clear decision framework 
on the uptake of new healthcare interventions in the country. Therefore, the issue of 
arbitrariness consideration might arise which will in turn affect the consistency and 
effectiveness of the decision. A country-specific economic evaluation of a new 
healthcare intervention is crucial to inform decision making. Therefore, the evaluation 
of the Malaysia-specific dengue vaccination impact, cost-effectiveness, and 
acceptance is crucial to inform decision making and facilitate its implementation. In 
addition, the determination of the public’s willingness to pay for a hypothetical dengue 
vaccine explores its potential for selling in the private markets. This would help the 
public healthcare decision makers as well as vaccine manufacturers to devise strategies 
in the implementation of vaccination campaign.   
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1.5 Study objectives 
Main objective: To evaluate the potential cost-effectiveness and to elicit the 
willingness-to-pay (WTP) value of dengue vaccine in Malaysia. 
Specific objective: 
1) To determine the potential health impact (dengue cases, dengue related deaths, life 
year lost and disability-adjusted-life-year) and economic impact (ambulatory 
dengue disease cost, hospitalized dengue disease cost, and productivity loss due to 
dengue disease) of dengue vaccination from both public provider and societal 
perspectives in Malaysia. 
2) To estimate the cost-effective threshold value of dengue vaccine in Malaysia 
employing cost-utility and cost-effectiveness analysis from both public provider 
and societal perspectives in Malaysia. 
3) To evaluate the acceptance of the hypothetical dengue vaccines among the general 
population in Penang state, Malaysia. 
4) To determine the willingness-to-pay (WTP), estimate the WTP values and evaluate 
the factors affecting the WTP towards the hypothetical dengue vaccines among the 











1.6 Significance of the study 
This study serves as the first empirical estimates of dengue vaccine’s impact, cost-
effective threshold value, and willingness-to-pay value in Malaysia. It acts as a 
valuable piece of evidence for the stakeholder and policy makers in the decision 
making when considering the integration of dengue vaccine into the National Dengue 
Strategic Plan (NDSP). This study also provides vaccine manufacturers a better picture 
of Malaysian’s perceptions of dengue fever and dengue vaccines which would assist 











The objective of this review is to review the state of the art for economic evaluation 
evidences of dengue vaccines focusing on the cost-effectiveness analysis (CEA), cost-
utility analysis (CUA), and willingness-to-pay (WTP). In addition, the relationship 
between acceptance and WTP towards dengue vaccine, dengue disease knowledge, 
dengue prevention practice, and vaccination attitude will also be reviewed. 
 
2.1 Conceptual framework of economic evaluation 
The conventional approach for a systematic comparison of cost and effects of health-
care interventions is through economic evaluation. CEA is a type of economic 
evaluation that involves the measurement of health effectiveness by natural units of 
health (number of cases/death averted) of an intervention in relative to cost. Though 
the measures of effectiveness by natural units might be helpful in comparing the 
effectiveness of different treatment, they lack the flexibility to compare across 
different programmes or diseases. CUA is a subset of CEA that utilizes composite 
index of health (reduction in Disability-Adjusted-Life-Year (DALY)/increase in 
Quality-Adjusted-Life-Year (QALY)) as a measurement of effectiveness (Drummond 
et al., 2005).  
Results of CEA and CUA are commonly summarized in Incremental Cost-
Effectiveness Ratio (ICER). ICER is a ratio calculated by dividing the incremental cost 
(the difference in cost) to the incremental effects (the difference in effects) between 
two alternatives (Berger et al., 2003). The numerator (cost) in ICER is expressed as 
monetary unit whereas the denominator (effect) is expressed in appropriate health 
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units. For example, life-year-lost (LYL) or death averted in CEA whereas QALY or 
DALY in CUA (Drummond et al., 2005). In short, ICER measures the additional cost 
per unit of health benefits gained in comparison between 2 interventions. The ICER 
formula is shown below: 
 
𝑰𝑪𝑬𝑹 =
𝑪𝒐𝒔𝒕 𝒐𝒇 𝑰𝒏𝒕𝒆𝒓𝒗𝒆𝒏𝒕𝒊𝒐𝒏 𝑨 − 𝑪𝒐𝒔𝒕 𝒐𝒇 𝑰𝒏𝒕𝒆𝒓𝒗𝒆𝒏𝒕𝒊𝒐𝒏 𝑩
𝑬𝒇𝒇𝒆𝒄𝒕 𝒐𝒇 𝑰𝒏𝒕𝒆𝒓𝒗𝒆𝒏𝒕𝒊𝒐𝒏 𝑨 − 𝑬𝒇𝒇𝒆𝒄𝒕 𝒐𝒇 𝑰𝒏𝒕𝒆𝒓𝒗𝒆𝒏𝒕𝒊𝒐𝒏 𝑩
 
 
QALY and DALY are universal health outcome measure used to quantify the 
impact of both changes in quality of life (morbidity) and quantity of life (mortality) in 
a single unit of measurement (Berger et al., 2003). QALY is a function of health-
related quality of life weight attached to the relevant year of life. Therefore, it is used 
primarily to correct someone’s life expectancy based on the levels of health-related 
quality of life predicted to experience throughout the course or part of their life 
(Drummond et al., 2005). On the other hand, DALY is a function of disability-related 
quality of life weight attached to the relevant year of life, calculated by the summation 
of years of life lost (YLL) due to premature mortality and years lived with disability 
(YLD) due to disease incidence (Drummond et al., 2005). A higher DALY score 
signifies a worst health. DALY is primarily a measure of disease burden incorporating 
the disability weight and was first introduced and applied in the 1990 Global Burden 
of Disease study (Salomon et al., 2013).  
The measurement of dengue disease burden using DALY was reported 
differently in different studies due to several factors. Firstly, in early studies, the 
DALY calculation only considered the DHF incidence and excluded the less severe 
DF; which leads to the underestimation of dengue cases by 2 to 10-fold (Beatty et al., 
2011). Second factor is the inconsistency in the application of disability scores and 
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duration of illness. Some early studies applied a very low disability scores (0.172 to 
0.211) and long duration of illness (30 days) (Beatty et al., 2011). In view of this, 
WHO revised the dengue disease burden estimates in 2004, where the disability score 
for DHF was increased to 0.5 but the duration of illness was shortened to 11 days. 
Furthermore, DF was included in the new estimates, with an assigned disability score 
of 0.211 and duration of illness of 5.5 days (Mathers et al., 2008). 
Economic evaluation has become an important tool for health policy decisions 
making for healthcare providers, payers and planners in evaluating the value for 
healthcare expenditure. In healthcare budget allocation, reimbursement decisions in 
vaccination are often weighted against other preventive and therapeutic interventions 
due to scarcity of health care budgets. This situation is especially common in low-and-
middle income countries (LMIC) which comprise almost 80% of the world population 
(Burchett et al., 2012). The design of economic evaluation before a vaccine has been 
fully introduced requires assumptions about variables such as efficacy, effectiveness, 
safety, dosage and costs. Furthermore, healthcare policy makers should consider 
country-specific demographic, epidemiological, clinical, and economic data in the 
modelling approaches to simulate disease transmission dynamics.  
 
2.1.1 Economic evaluation using decision-analytic modelling 
Decision-analytic modelling offers a framework for decision-making under conditions 
of uncertainty. Specifically, it defines a set of mathematical relationship between 
entities characterizing the range of possible disease prognoses and the impacts of 
alternative interventions (Drummond et al., 2015). Several types of model are used for 
economic evaluation, including decision tree, Markov, discrete event simulation and 
dynamic transmission models. Identifying an appropriate model type is a very crucial 
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stage in the decision modelling process. The decision to select a model in a study 
should depend on the overall objective of the economic evaluation, the nature of the 
disease process, and impacts of the interventions (Drummond et al., 2015). In the 
context of selecting an appropriate model to represent the dengue disease process in 
this study, 2 models will be discussed in this review, i.e. the Markov model and the 
dynamic transmission model. 
 Markov models are based on a series of “states” that a patient can occupy at a 
given point in time. Time elapses explicitly with a Markov model, with the probability 
of a patient occupying a given state assessed over a series of discrete time periods, 
called “cycles”. The length of each cycle will depend on the disease and interventions 
being evaluated. The speed with which patients move between the states in the model 
is determined by a set of transition probabilities. Each state in the model generally has 
a cost and an outcome associated with it. The costs and values of each Markov state 
are weighted by the time a patient spends in that state. This is made up of 2 stages. 
Stage 1 calculates the probability of a patient being in each state for each cycle; stage 
2 calculates the expected costs and effects. A cohort simulation is undertaken for each 
option being evaluated (Drummond et al., 2015). Markov model assumes that the 
individual being modelled are independent from each other with respect to their health. 
This independence assumption may be untenable in the context of infectious disease 
where the incidence of new infections depends on the existing number of individuals 
who are infected. Furthermore, the incidence of an infection changes dynamically 
during an epidemic. Therefore, models relating to infectious diseases may need to 
consider a dynamic transmission model (Drummond et al., 2015). 
 The transmissible nature of infectious diseases is what sets them apart from 
other disease models. The probability of a susceptible individual becoming infected at 
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any one point in time (the force of infection) is related to the number of infectious 
individuals in the population, will change over time, and will feed back into the future 
force of infection. These nonlinear interactions produce transmission dynamics that 
require specific consideration when modelling an intervention that has an impact on 
the transmission of a pathogen. Dynamic transmission models can reproduce the direct 
and indirect effects (individuals not reached by the program can still benefit by 
experiencing a lower infection risk) that may arise from a communicable disease 
control program (Pitman et al., 2012). 
 A dynamic transmission model can be deterministic or stochastic. 
Deterministic models, in which every state variable is uniquely determined by the 
parameter values and previous state-variable values, always give the same results for 
the same starting conditions and parameter values. They approximate a system's 
average behaviour and are most appropriate when all subgroups are large. They are 
comparatively easy to fit to data and thus are easier to calibrate. In a stochastic model, 
the state variables are described by probability distributions, incorporating the role of 
chance. This often occurs in small populations or when a subgroup is small (e.g. at an 
epidemic's beginning or ends) that is, when local extinction is likely (Pitman et al., 
2012). 
 
2.1.2  Comparative modelling of dengue vaccine public health impact (CMDVI) 
The WHO initiated the “Comparative modelling of dengue vaccine public health 
impact” (CMDVI) consortium (World Health Organization, 2016a) in April 2015 to 
develop model based predictions of the long-term safety, health and economic impact 
of Dengvaxia®, and to inform recommendations to the WHO Strategic Advisory 
Group of Experts on Immunization (WHO-SAGE). Any group that has a dynamic 
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transmission model of dengue vaccination that had been used to examine the potential 
public health impact of vaccination and where results and key features have been 
documented (in either a peer reviewed journal article, or an unpublished technical 
documentation to the standard of a journal article) was invited to join. 
Four out of eight of the models in the evaluation were stochastic simulation 
models (University of Florida, University of Western Australia, University of Notre 
Dame, and Exeter University/Oxford University) while the other four were 
deterministic compartmental models (Sanofi Pasteur, Johns Hopkins 
University/University of Florida, Imperial College, and Duke University). All the 
models mentioned above have been described in detail in their respective publications 
(Nagao and Koelle, 2008, Lourenço and Recker, 2013, Rodriguez-Barraquer et al., 
2014, Rodriguez-Barraquer et al., 2013, Coudeville et al., 2015, Hladish et al., 2016, 
Karl et al., 2014). 
CMDVI found that all models predicted a routine vaccination of children age 
9 years old with Dengvaxia® at 80% vaccine coverage would reduce dengue disease 
in moderate to high transmission intensity settings (i.e. where seroprevalence of 
children age 9 years old more than 50%). The reduction in dengue-related 
hospitalization was highest in high transmission intensity settings (i.e. where 
seroprevalence of children age 9 years old more than 70%). Besides, all the models 
predicted that the optimal age for routine vaccination decreased as the transmission 
intensity increased.  
All models measured the health effects in terms of DALY. The cost-
effectiveness evaluation revealed that vaccination will only be cost-effective if the 
total cost of full vaccination per person is below US$40 from the public payer 
